PMVP
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
PMV Pharmaceuticals, Inc. (PMVP) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Profitability (D+). The rating has held at C+ for 4 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | B+ (3.7) | C (2.2) | D+ (1.7) | B- (3.0) | C+ (2.6) | C+ (2.7) |
| 2026-11-07 | A- (3.9) | C (2.4) | D+ (1.8) | B (3.3) | C+ (2.7) | C+ (2.8) |
| 2026-10-31 | B+ (3.7) | C (2.2) | C- (1.9) | B+ (3.8) | C+ (2.7) | C+ (2.8) |
| 2026-10-24 | B+ (3.7) | C (2.2) | C- (1.9) | C+ (2.7) | C+ (2.6) | C+ (2.6) |
| 2026-10-17 | B+ (3.7) | C (2.2) | C- (1.9) | C+ (2.8) | C+ (2.6) | C+ (2.6) |